<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>perioperative combination therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/perioperative-combination-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 08 Jan 2026 03:48:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>perioperative combination therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Tislelizumab-Lenvatinib Shows Promise for High-Risk Liver Cancer</title>
		<link>https://bioengineer.org/tislelizumab-lenvatinib-shows-promise-for-high-risk-liver-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 08 Jan 2026 03:48:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[high-risk recurrence]]></category>
		<category><![CDATA[perioperative combination therapy]]></category>
		<category><![CDATA[phase II trial]]></category>
		<category><![CDATA[tislelizumab-lenvatinib]]></category>
		<guid isPermaLink="false">https://bioengineer.org/tislelizumab-lenvatinib-shows-promise-for-high-risk-liver-cancer/</guid>

					<description><![CDATA[In a groundbreaking advance that could redefine the therapeutic landscape for liver cancer, a new single-arm phase II clinical trial has demonstrated the potential of combining perioperative tislelizumab with lenvatinib to treat resectable hepatocellular carcinoma (HCC). This malignancy, notorious for its high rate of recurrence after surgical resection, has long posed formidable challenges to oncologists [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314729</post-id>	</item>
	</channel>
</rss>
